Search
for
Sort by
Research 121–150 of 1000+
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- The JAK/STAT signaling pathway: from bench to clinic
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Janus kinase inhibitors in dermatology: A systematic review
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Topical Janus kinase inhibitors: A review of applications in dermatology
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Janus Kinase Inhibitors for Alopecia Areata
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Janus kinase inhibitors for alopecia areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata